Calypte Only Company with Full Menu of Tests.

wie wärs mit einen Auftrag über 10.000.000 Tests ?
Na das wär doch was oder ?

langsam wirds eng für mich !
Kommt schon Leute iwe wärs heut mit einer Auftragsmeldung über ein paar Millionen
das des Kurs anspringt !

   

Ich sehe:Intakter Abwärtstrend(fallende Gd`38/100/200)bei einem auf Jahressicht stabileren   Gesamtmarkt! Fallende Preise trotz grüner Volumenspitzen!
Ich denke: News sind bei diesem Wert nicht zu gebrauchen! Der Wert wird bereits seit Jahren in vielen Foren gepuscht!

Fazit: Für mich kein Kauf  

Gruß hemadun

bei Caly/CYPT/HIV sprich große Aufträge das hat mit Chartanalyse gar nicht mehr zu tun.
Hop oder Top bei 0,10 $ bin ich draussen.
Lucky

     

Für mich sind Hoffnungen und Ängste im Chart bereits enthalten!

Gruß hemadun  

Grüße, ZN

tja Bio so is Börse hätte aber auch funktionieren könen das ganze !

10/27/04 Calypte Biomedical to Host 3rd Quarter Conference Call  
10/25/04 Calypte Biomedical to Begin Shipping HIV-1 Incidence Test  
10/05/04 Calypte Biomedical Announces Licensing Agreement with Ani Biotech  
10/04/04 Calypte Biomedical Receives Rapid Test HIV-2 Patent License From Bio-Rad  
09/15/04 Calypte Biomedical to Ring Opening Bell at the AMEX  
08/16/04 Calypte Biomedical Approved for Listing on AMEX: HIV  
08/12/04 Calypte Biomedical Announces Second Quarter and Six-Month Financial Results  
08/10/04 Calypte Biomedical to Host 2nd Quarter Conference Call  
08/09/04 Calypte Biomedical Announces Signing of Sublicense Agreement with Abbott Laboratories  
07/21/04 Calypte Biomedical To Host Conference Call  
07/19/04 Calypte Biomedical Issues Update on Informal SEC Inquiry  
07/15/04 Calypte Biomedical Presents Results of Its Rapid HIV-1/2 Field Trial Tests at the XV International AIDS Conference in Bangkok  
07/13/04 Calypte Biomedical Raises an Additional $1.5 Million in Private Placement  
07/01/04 Calypte Biomedical Announces Board Member Resignation  
06/24/04 Calypte's Rockville, Maryland Facility Receives Quality System Certification to ISO 13485:1996  
06/16/04 Calypte Files Registration Statement  
06/01/04 Calypte Biomedical Raises $9.3 Million in Private Placement  
05/25/04 Calypte Developing HIV-1/2 Oral Fluid Rapid Tests  
05/13/04 Calypte Announces First Quarter Financial Results  
05/13/04 Calypte Biomedical Corporation: First Quarter Earnings Conference Call  
05/13/04 Calypte Enters Into Memorandum of Understanding with Beijing Tiantan Biological Products  
05/11/04 Calypte Finalizes Manufacturing Agreement for Rapid Tests  
04/14/04 Calypte Announces Execution of a Research and Development Agreement With CDC for Rapid HIV Incidence Test  
04/12/04 Calypte Announces License From CDC for HIV Incidence Test  
04/06/04 Calypte Appoints New Board Member  
04/01/04 Calypte Launches International Manufacturing Initiative of its Rapid HIV Type 1 and HIV Type 2 Tests  
03/23/04 Calypte Announces Fourth Quarter and Year End Results  
03/19/04 Calypte Biomedical Corporation 2003 Fourth Quarter/Year-End Conference Call  
01/27/04 Calypte Biomedical to Host Conference Call On January 29th; Newly Appointed CEO Dr. Richard George and VP of Operations Richard VanMaanen to Speak  
01/20/04 Calypte Biomedical Appoints Dr. Richard George as President and CEO and Richard Van Maanen as Vice President of Operations
12/02/03 Calypte Biomedical and Earvin 'Magic' Johnson Commemorate World AIDS Day December 1st  
11/14/03 Calypte Biomedical Announces Third Quarter and Nine-Month Financial Results  
11/14/03 Calypte Biomedical to Host 3rd Quarter Financial Results Conference Call On November 17  
11/06/03 Calypte Biomedical Submits Investigational Device Exemption Application for HIV-1 Rapid Blood Test  
11/03/03 Calypte Biomedical to File Form 8K  
10/17/03 Calypte Biomedical to Present at Rodman & Renshaw Techvest Healthcare Conference  
10/17/03 Calypte's Urine Based HIV Test Receives Approval in the Republic of Kenya  
10/16/03 Calypte Biomedical Corporation and LabOne Sign Multi-Year Agreement  
10/09/03 Calypte Receives Initial Order From Botswana  
10/08/03 Calypte Completes China Clinical Trials  
10/02/03 Marr Technologies Increases Investment in Calypte Biomedical Corporation  
10/01/03 Calypte Biomedical Corporation Plans New Initiative With The AIDS Action Council In Africa  
09/24/03 Calypte Biomedical to Test its Urine Based HIV-1 Test in Tanzania, Rwanda, Burundi and Botswana  
09/09/03 Calypte's HIV-1 Antibody Tests Approved For Distribution in the Republic of Uganda  
09/02/03 Calypte Receives $10 Million Investment  
08/12/03 Calypte Biomedical Announces Resumption of Product Distribution in China  
07/31/03 Calypte Biomedical Announces $2.5 Million Investment  
07/31/03 Calypte Biomedical Announces Second Quarter and Six-Month Financial Results  
07/30/03 CEOcast Initiates Coverage of Calypte Biomedical  
07/25/03 Calypte Biomedical to Host 2nd Quarter Financial Results Conference Call On July 31  
07/10/03 Calypte Adds Second China Distributor  
06/30/03 Calypte Announces Dr. J. Richard George to Head Its Rapid HIV Business  
06/27/03 Calypte Announces Senior Management Change; Nancy Katz to Depart the Company  
06/26/03 Calypte Receives Another Order from Its Primary China Distributor for 150,000 Tests  
06/25/03 Calypte Adds Taiwan ROC Distributor; Enfield Medical Co. Ltd. Expands Calypte's Asian Coverage  
06/24/03 Calypte Receives Initial Order for the Middle East  
06/13/03 Calypte Biomedical Announces Symbol Change  
06/03/03 Calypte Names President and Chief Operating Officer to Ensure a More Efficient Transition into Its Marketing and Sales Phase  
05/28/03 Calypte Implements Reverse Stock Split; $15 Billion Emergency Plan for AIDS Relief Signed by President Bush  
05/23/03 Calypte Receives FDA Approvals on Revised Labeling for Urine Screening and Supplemental Tests; Provides Opportunity for Increased Marketing Opportunities  
05/22/03 Calypte Biomedical Partners with Planned Parenthood Federation of America to Fight the Spread of HIV  
05/21/03 Calypte Biomedical Corporation Holds Annual Meeting of Shareholders; Obtains Shareholder Approval for All Agenda Items  
05/06/03 FDA Authorizes Use of Calypte HIV-1 Serum Western Blot as Supplemental Test for HIV Rapid Products; Expands Market for Cambridge Biotech Western Blot Serum/Plasma Test  
04/29/03 Earvin ``Magic'' Johnson and Calypte Biomedical Team-up to Fight the Spread of AIDS  
04/24/03 Calypte Announces First Quarter Financial Results  
04/23/03 Calypte Biomedical Reschedules First Quarter Earnings Conference Call; First Quarter Financials Will Be Disseminated as Scheduled  
04/21/03 Calypte Biomedical to Announce First Quarter 2003 Financial Results  
04/10/03 Cambridge Biotech Serum Western Blot Update; Adaltis U.S. Inc. Grows Their Customer Base for Calypte Product  
04/04/03 Calypte Biomedical Corporation Files Preliminary Proxy Statement  
04/03/03 Calypte Expands Distribution into the Middle East; Mistaire LLC Selected to Distribute Calypte Products Throughout the GCC  
03/19/03 Harlem Congregations for Community Improvement Plans to Expand Use of Calypte's Urine HIV-1 Antibody Tests  
03/10/03 Calypte Biomedical Reports Three New Insurance Customers; Continues Insurance Market Penetration  
03/04/03 Calypte Receives an Additional Approval Eliminating FDA Lot Release Testing; Reduces Production-to-Market Time for HIV-1 Urine Western Blot Test  
03/03/03 Calypte's Urine HIV-1 Antibody Tests Selected for Important Faith-Based HIV Testing Initiative  
02/27/03 Calypte Announces Fourth Quarter and Year-End Financial Results; Adds Planned Parenthood Golden Gate to Customer Base  
02/27/03 Planned Parenthood Golden Gate to Offer Calypte's Urine HIV-1 Antibody Tests; Earnings Results Conference Call to be Conducted Today  
02/19/03 PathNet Laboratory to Offer Calypte Urine HIV Testing; Expands Urine Testing Access to Women's Health  
02/18/03 StockMac.com Focuses on Calypte Biomedical in its Market Awareness Newsletter  
02/18/03 Calypte Announces Results of Special Shareholder Meeting and Preliminary Unaudited Fourth Quarter 2002 Results  
02/06/03 Calypte Biomedical to Announce Fourth Quarter and Year-End 2002 Financial Results On February 27th  
02/05/03 Calypte Biomedical to Present at the Wall Street Analyst Forum 47Th Annual Institutional Investor Conference  
02/03/03 Calypte Comments On President Bush's Plans for AIDS Relief; Calypte's Safe Blood for Africa Relationship Focuses on HIV Testing  
01/27/03 Calypte HIV-1 Urine Tests Used in Study Led by Johns Hopkins for HIV Testing in High Risk Communities; Study Concluded Urine Tests are Effective Tools for HIV Screening  
01/10/03 J. Richard George, CDC and HIV Veteran Joins Calypte as VP of Government Affairs  
01/08/03 Calypte Receives Exemption from FDA Lot Release Testing; Production-to-Market Time for HIV-1 Urine EIA Test Significantly Reduced  
01/06/03 Calypte Receives Second Commercial Order from China Distributor and Payment for First Order; New Order for 160,000 Tests to Ship in February 2003
12/13/02 Calypte Signs Memorandum of Understanding with the Safe Blood for Africa Foundation  
12/10/02 Community Healthcare Network To Offer Calypte's Urine HIV-1 Tests; Community Healthcare Network Celebrates World AIDS Day with ``Living'' Quilt  
12/09/02 Odell Mays Joins Calypte Biomedical Sales Team; Significantly Strengthens Company's Efforts to Expand Urine HIV Testing in Public Health  
12/06/02 Calypte Biomedical Presents at Healthcare Conference  
12/03/02 Calypte Nominates Dian J. Harrison to Board of Directors; Planned Parenthood Golden Gate CEO Brings Wealth of Experience Promoting Health Issues Vital to Calypte's Cause  
11/25/02 Calypte's Chairman Comments on State of HIV Testing Marketplace  
11/13/02 Calypte's Alameda Facility Passes ISO 9001 Follow-up Inspection  
10/24/02 Calypte Announces Third Quarter and Nine-Month Financial Results; Management Expects Sequential Fourth Quarter Revenue Growth of at Least 50 to 75%  
10/16/02 Calypte Biomedical to Announce Third Quarter 2002 Financial Results On October 24th  
10/15/02 Calypte Receives First Commercial Order in China With New Distributor; Order for 100,000 Tests to Ship in Fourth Quarter 2002  
10/09/02 Calypte Reports On Positive Outcome of pre-IDE Meeting On the Rapid HIV Urine Test  
10/08/02 Calypte Biomedical Kicks Off Retail Investor Initiative With Presentation At SCIA Conference  
09/26/02 Calypte Biomedical Reports On US Conference on AIDS  
09/19/02 Calypte's Urine HIV-1 Antibody Test Now Approved for Life Insurance Screening In All 50 States  
09/12/02 Calypte Biomedical to Attend US Conference on AIDS  
09/03/02 HIV Pioneer Encourages Chinese Health Authorities to Take 'Full Advantage' Of Calypte's HIV-1 Urine Screening Test  
08/27/02 Calypte to Accelerate Development of Rapid HIV Urine Test  
08/14/02 Calypte Files 10-Q and Submits Financial Certification With the SEC  
08/07/02 Calypte Receives Initial Order for Urine HIV Tests From West Africa  
07/24/02 Calypte Announces Second Quarter Financial Results; Company to Accelerate U.S. Studies of Rapid HIV Test  
07/19/02 Calypte Announces Second Quarter Conference Call and Webcast  
07/19/02 Calypte Amends Preliminary Proxy; Removes Proposal Seeking Approval for Reverse Stock Split  
07/18/02 Calypte Seeks Shareholder Approval to Position Company for Future Acquisitions, Financings, and Employee Benefit Plans  
07/11/02 Dr. Luc Montagnier, Co-Discoverer of HIV-1 and HIV-2, to Serve as Consultant to Calypte  
07/08/02 Calypte to Present ``Bloodless'' Rapid HIV-1 Test Data at XIV International AIDS Conference  
06/25/02 Adaltis Inc. to Distribute Calypte Serum Test Worldwide  
06/11/02 Calypte Gains Distribution Rights for FDA-Cleared Urine Test of Liver Function; Exclusive Rights for US and Canada Insurance Market  
06/05/02 Calypte Biomedical Resumes Normal Production Following Previously Announced Wind-Down of Activities; Expects to Resume Shipments of Its Western Blot Test Early Next Week  
05/31/02 Calypte Biomedical Announces the Appointment of Martin Landau to Its Board of Directors  
05/24/02 Calypte Biomedical Announces Completion of Over $2.7 Million In New Funding  
05/20/02 Calypte Announces First Quarter Financial Results  
05/15/02 Calypte Announces First Quarter Results Conference Call and Webcast  
05/13/02 Calypte Biomedical Announces Appointment of New Executive Chairman and Continuation of Ongoing Business  
04/17/02 Calypte Announces a Winding Down of Operations  
04/01/02 Vermont Issues Guidelines for Life Insurance HIV Testing and Consent; Includes Procedure for Urine HIV-1 Antibody Testing  
03/28/02 Calypte Updates Guidance for Current Quarter and 2002; First Quarter Results To Be Released May 1st  
03/13/02 Calypte HIV-1 Urine EIA exhibits strong performance in Brazilian Study; Correctly Identifies All Positives With Major HIV-1 Subtypes  
03/07/02 University of North Carolina Selects Calypte's Urine Test for International HIV/AIDS Testing Effort  
02/19/02 Calypte Biomedical Presents At Wall Street Analyst Forum; Shares plans for future growth with analysts, portfolio managers at key New York conference  
02/12/02 Calypte Biomedical to Present At Wall Street Analyst Forum; Management to Address Analysts, Portfolio Managers On February 14 At Institutional Conference  
02/12/02 Calypte Completes Private Placement of $850,000 in Convertible Debentures and Obtains Additional Financing Commitment  
02/11/02 Calypte Reports Fourth Quarter and Full Year 2001 Financial Results; Revenues More than Double Compared With Prior Year  
02/07/02 Calypte Announces Preliminary 2001 Operating Results  
02/04/02 Calypte Biomedical Retains Investor Relations Network To Direct Its Financial Public Relations Programs  
01/30/02 Unilab, California's Largest Lab Testing Provider, Begins Offering Calypte's HIV-1 Urine Tests  
01/10/02 Calypte Announces Year-End Financial Calendar
12/18/01 Calypte Biomedical Elects Richard Brounstein Executive Vice President and Chief Financial Officer; Also Appointed to Board of Directors  
11/30/01 Calypte Announces Extended Expiration Dating for HIV-1 Western Blot Products  
11/28/01 Calypte Announces Equity Offering to International Investors  
11/28/01 Calypte Secures Additional Equity Financing; Investors include Members of Calypte Board and Management  
11/23/01 Calypte Biomedical Signs Key Agreement to Develop New Urine-based Test; Will Diagnose HIV Infection in as Little as 15 Minutes  
11/14/01 Planned Parenthood Mar Monte to Offer Calypte's Urine HIV-1 Antibody Tests  
11/07/01 Calypte Biomedical Reports 40% Insurance Sales Growth in Third Quarter  
10/31/01 Calypte's HIV-1 Antibody Urine Test Included On CAADPE Purchasing Contract; Calypte's Distributor, MEDITECH INTERNATIONAL, Awarded Purchasing Contract With CAADPE  
10/18/01 Calypte Reports Third Quarter 2001 Financial Results; Revenues Increase 75% Compared With Third Quarter 2000  
10/15/01 Calypte Biomedical Corporation Third Quarter Earnings Conference Call Friday, October 19, 2001, at 11:00 a.m. ET, 8 a.m. PT  
10/09/01 Calypte's Commitment to Compliance and Quality Yields Improved Operations, Cost Savings  
10/02/01 Calypte Provides Status Update; Receives First Substantial China Order  
09/28/01 Calypte Biomedical Corporation Announces Conference Call Monday, Oct. 1, 2001, at 11:00 a.m. ET -- 8 a.m. PT  
09/27/01 More Markets to Gain Access to Calypte HIV-1 Antibody Urine Test; Calypte Expands Market Opportunities Through Distribution Agreement With MEDITECH INTERNATIONAL  
09/26/01 Calypte Stockholders Approve Proxy Proposals; Company Committed to Protecting Nation's Blood Supply  
09/18/01 Calypte Announces 'Grassroots' Efforts For HIV-1 Urine Testing; New and Improved Sentinel Testing Service Launched  
09/05/01 Calypte Secures Equity Line Financing Commitment  
07/19/01 Calypte Reports Second Quarter 2001 Results  
07/17/01 Calypte to Host Conference Call to Discuss Second Quarter 2001 Earnings Results  
07/13/01 Calypte Biomedical Announces Nasdaq Ruling  
06/27/01 FDA Approves Conversion of Calypte Urine Western Blot BLA to Premarket Approval Status  
06/27/01 Calypte Provides Status Update  
05/16/01 Calypte Biomedical Notified of Potential Nasdaq Delisting  
04/26/01 Calypte Reports First Quarter 2001 Results  
04/23/01 Calypte Sells Minority Stake in Pepgen; Affirms Focus on Core Diagnostic Business  
04/13/01 Calypte to Host Conference Call  
04/12/01 Calypte Announces First Quarter Revenues and Status; Company Achieves Record Revenues; Seeks Financing Alternatives and Faces Possible Delisting From Nasdaq SmallCap Market  
03/27/01 Calypte Biomedical Facility Awarded ISO 9001 Certification  
03/02/01 Calypte Reports Fourth Quarter and Year-End 2000 Results  
03/02/01 Calypte to Host Conference Call to Discuss Fourth Quarter and Year-End 2000 Earnings Results  
02/14/01 Calypte's HIV-1 Urine Test Approved For Use In Malaysia; Local Distributor Selected to Handle Sales and Logistics  
02/13/01 Calypte Registration Statement On Form S-2 Declared Effective; Registration Is For Resale of Shares Pursuant to Equity Line Facility  
02/06/01 Calypte's HIV-1 Serum Western Blot Assay to be Distributed by Organon-Teknika; Agreement Positions Calypte as a Major Manufacturer of Supplemental HIV Blood Tests  
01/25/01 Calypte Reaffirms $25 Million Equity Financing Commitment; Company Amends Equity Line Facility and Files New Registration Statement with SEC  
01/22/01 Calypte's Alameda Manufacturing Facility Approved by FDA: Alameda Facility Will Allow Increased Production of HIV-1 Antibody Urine Test  
01/22/01 Calypte Biomedical Raises up to $1.1 Million in Debenture Issuance  
01/02/01 Calypte Biomedical Appoints New General Manager of Rockville Manufacturing Facility
12/20/00 International Studies Demonstrate Calypte's Modified HIV-1 Antibody Urine Test Competitive With Serum Testing  
12/20/00 Calypte's New California Manufacturing Facility Gains State Approval - Company Expands Distribution Into Developing Countries  
12/04/00 Calypte Biomedical and Becton, Dickinson and Company Announce New One-stop Testing Service  
11/21/00 Calypte Supports World AIDS Day 2000; Company Donates Its HIV-1 Antibody Urine Test to Key Sites Across U.S.  
11/03/00 Calypte Secures $25 Million Equity Financing Commitment  
11/02/00 Calypte Reports Third Quarter Results  
11/02/00 Calypte Teams With Osborn to Develop Two Rapid HIV Antibody Urine Tests; Faster Tests Can Lead to More People Learning Their HIV Status  
11/02/00 Calypte Signs Memorandum With Marukin as Step Toward Becoming Exclusive Distributor of Urine-Based Liver Assay for Insurance Testing Market  
10/26/00 Calypte Applauds the Passage of Needlestick Safety and Prevention Bill  
10/12/00 Calypte Biomedical Promotes Sheila Borland To National Sales Manager  
08/24/00 Calypte Biomedical Names Dr. Lei Xu Asia Regional Business Manager  
08/24/00 Calypte's HIV-1 Urine Test Approved for Use in People's Republic of China  
08/09/00 Calypte Reports Second Quarter Results  
08/09/00 Calypte Biomedical Appoints New Government Relations Director  
08/09/00 More Than 40 Countries in Sub-Saharan Africa to Gain Access to Calypte's HIV-1 Antibody Urine Test  
07/24/00 Calypte Biomedical Names Dr. Julie Hoffman Director of Quality Assurance / Quality Control  
06/30/00 Urine Testing Benefits Greater Than Blood in Insurance Setting  
06/23/00 Calypte Co-Sponsors National HIV Testing Day 2000; Recent CDC Study Found 90 Percent Said They Changed Their Sexual Behavior After Learning They Were Infected  
06/13/00 Calypte Biomedical Announces Senior Management Promotions  
06/13/00 Calypte Biomedical Launches Its New Web Site Completely Revamped Site Puts Wealth of HIV Testing Information Just a Click Away  
06/12/00 Calypte Appoints Distributor for Its HIV-1 Urine Test in People's Republic of China  
06/06/00 Calypte to Distribute Its HIV-1 Urine Test in South Africa  
05/22/00 Notice of Calypte Biomedical Annual Meeting of Stockholders to be Held On June 13, 2000  
05/11/00 Calypte Biomedical Signs Exclusive Agreement to Distribute Urine-based HIV Testing Products in Brazil  
05/10/00 Calypte Biomedical Launches First Urine-based Testing Service in United States for HIV and STD Exposure  
05/10/00 Calypte Reports First Quarter Results  
04/13/00 Calypte Announces Closing Of $8.4 Million Private Placement  
03/09/00 Calypte Founder Announces Formation of Genomics Venture  
03/09/00 Calypte Reports Fourth Quarter and Year-End Results  
03/03/00 Calypte Raises $8.4 Million in Private Placement

Dr. George continued, "In accordance with company policy, we will not provide interim data on assay performance in this clinical trial. However, we will release the performance results when the trials have been completed and certified by our Chinese contractor. Our objective is to file the required regulatory applications with the Chinese FDA (SFDA) in early 2005. Based on our understanding of the current Chinese regulatory submission process, we expect to receive a response from SFDA by approximately mid-2005. We also expect to have production from our manufacturing plant available by that time to support the launch into China, contingent upon regulatory approval, in the second half of 2005. We expect to have an initial production capacity of over 30 million tests per year for the Chinese market."

There are a reported 840,000 adults and children in China living with HIV/AIDS today, and according to the Bill & Melinda Gates Foundation, China is one of the "next wave" countries where the number of infections is expected to grow to 15 million by 2010. China has recognized this problem and acknowledged its testing gap. The annual AIDS testing level is currently estimated at 1.5% of the population. The Chinese government has recently announced its commitment to offer voluntary HIV testing to its entire 1.36 billion-population. Calypte believes that the only effective way to manage such numbers is to utilize trained non-professionals who would be able to execute such a program based on safe, alternative fluid testing -- oral fluid or urine -- HIV 1/2 tests. There are other focused and large markets within China where testing is mandated, such as population control, prisons and immigration

quäle dich ruhig weiterhin. jetzt habt ihr schon widerstände bei der 0,13$


resist. 0.33 4
resist. 0.28 2
resist. 0.27 10
resist. 0.23 15
resist. 0.22 8
resist. 0.21 11
resist. 0.20 34
resist. 0.18 12
resist. 0.17 4
resist. 0.16 2
resist. 0.15 7
resist. 0.14 2
resist. 0.13 8


hast du dir mal den durchschnittshandelskurs von gestern angesehen? garantiert nein!!! er lag bei 0,132. d.h. der überwiegende teil der aktien wurde schon zu 0,13$ gehandelt. es geht immer tiefer. vergíß deine PRs von caly. die sind nur gemacht worden, die leute bei der stange zu halten.

viele buchstaben mit nichts dahinter!!!

wo sind denn eure umsätze?

eure zulassungen?

eure chinaresultate?

eurem maximdeal?

ok sollte das bei Caly daneben gegagen sein ist das mein Problem ich wußte was ich mach.
Was du mir wünscht einen gap down oder sonst was is ok danke.

Aber eins mein kleiner Junge mußt du merken; jeder handelt nach seinen Geldbeutel und Möglichkeiten und den Verlust,wenn ich bei 0,10 Verkauf hätte, bringt mich nicht um.

 

orasure bald wieder bei 10,00$.

soviel zu deren einbruch...


Time & Sales most recent  next page
Rec. Time Action Price Volume
9:34:20 AM Ask 9.73  200  
9:34:18 AM Trade 9.71  1000  
9:34:12 AM Bid 9.71  400  
9:34:12 AM Ask 9.73  400  
9:34:12 AM Trade 9.72  1000  
9:34:12 AM Trade 9.72  900  
9:34:12 AM Bid 9.7  600  
9:34:12 AM Bid 9.7  1000  
9:34:10 AM Trade 9.72  100  
9:34:10 AM Bid 9.72  1000  
9:34:10 AM Ask 9.73  300  
9:34:04 AM Ask 9.73  200  
9:34:04 AM Ask 9.73  400  
9:34:02 AM Trade 9.72  100  
9:34:02 AM Bid 9.72  1900  
9:33:26 AM Bid 9.72  2000  

STROOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONNNNNNNNGGGG!!!!!!!!!!!!!!

muhahahhahahahahahahahahahahaahahahahahahahahahaah!!!!!!!!!!!!!!1­

du hast weder orasure Anteile noch Trip Anteile ich denke du hast gar nichts mehr außer
ein Bedürfnis hier in WO oder RB dich mit zuteilen.

Gib dir mal Tipp kostenlos.
Chatträume gibt es genug da kannst du dich mitteilen ohne ende und viele die genau das gleiche Problem haben wie du, lesen mit und geben dir Recht.

DADURCH KANNST DU DEIN SELBTWERTGEFÜHL WIEDER AUFBAUEN; UND ALS ORDENTLICHES MITGLIED IN DER GESELLSCHAFT WIEDER TEILHABEN:

LUCKY

ist der durchschnittliche tradingkurs heute bei 0,1396, was daraurf hindeutet, dass überwiegend ins ask gekauft wurde. na immerhin etwas...


Time & Sales most recent  next page
Rec. Time Action Price Volume
1:03:00 PM Trade 0.14  5000  
1:03:00 PM Ask 0.14  146400  
1:01:18 PM Bid 0.13  298000  
12:44:22 PM Bid 0.13  277500  
12:44:22 PM Trade 0.13  100  
12:41:10 PM Bid 0.13  277500  
12:35:12 PM Bid 0.13  268000  
12:10:04 PM Trade 0.13  500  
12:10:02 PM Bid 0.13  276000  
11:49:18 AM Ask 0.14  151400  
11:47:42 AM Ask 0.14  134800  
11:46:54 AM Ask 0.14  151400  
11:43:12 AM Bid 0.13  276500  
11:43:12 AM Trade 0.13  2000  
11:28:00 AM Bid 0.13  278500  
11:27:10 AM Bid 0.13  277500  
11:17:22 AM Bid 0.13  276500  

USA ist heute geschlossen !